A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma
| Autor: | R. S. de Jong, J. M. Smit, M E T Tesselaar, M B L Leys, H P Sleeboom, D ten Bokkel Huinink, J J Arends, J.W.R. Nortier |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Diarrhea Male Cancer Research medicine.medical_specialty Pancreatic disease Neutropenia SCHEDULES pancreatic cancer Phases of clinical research Thiophenes Gastroenterology Deoxycytidine Drug Administration Schedule Internal medicine Pancreatic cancer Antineoplastic Combined Chemotherapy Protocols Clinical Studies medicine Humans COMBINATION Aged CANCER-TREATMENT business.industry raltitrexed gemcitabine ADENOCARCINOMA Middle Aged phase II CHEMOTHERAPY medicine.disease Gemcitabine DOSE-RATE INFUSION FLUOROURACIL Surgery Pancreatic Neoplasms Survival Rate Oncology Tolerability Fluorouracil Quinazolines SURVIVAL 5-FLUOROURACIL Female TRIAL business Raltitrexed medicine.drug |
| Zdroj: | British Journal of Cancer British Jounal of Cancer, 92(3), 445-448. Nature Publishing Group |
| ISSN: | 0007-0920 |
| Popis: | Advanced adenocarcinoma of the pancreas has a very poor prognosis. The aim of this study was to assess the efficacy and tolerability of a combination of the chemotherapeutic agents gemcitabine and raltitrexed. Chemonaive patients with advanced adenocarcinoma of the pancreas were treated with a combination of raltitrexed (3.5 mg m(-2) on day 1 of a 21-day treatment cycle) and gemcitabine (800 mg m(-2) intravenously ( i. v.) on days 1 and 8 of a 21-day cycle). Between April 2000 and February 2003, 27 patients were enrolled onto the study. The mean duration of treatment was 11 weeks. Four of 27 patients experienced at least one episode of grade 3 or 4 neutropenia. One patient with grade 4 neutropenia died due to sepsis. Four of 27 patients experienced grade 4 diarrhoea. There was one partial remission (4%) and 12 patients experienced disease stabilisation (44%). The 6-month and 1-year survival rates were 37 and 11%, respectively. Symptomatic benefit occurred in seven (26%) patients. We conclude that a combination of raltitrexed and gemcitabine, using the schedule and doses in this study, cannot be recommended for patients with advanced pancreatic cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|